1. Home
  2. NA vs PMVP Comparison

NA vs PMVP Comparison

Compare NA & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NA

Nano Labs Ltd

HOLD

Current Price

$2.41

Market Cap

68.2M

Sector

Technology

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.44

Market Cap

73.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NA
PMVP
Founded
2019
2013
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.2M
73.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
NA
PMVP
Price
$2.41
$1.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
46.2K
441.8K
Earning Date
03-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.41
$0.83
52 Week High
$31.48
$1.88

Technical Indicators

Market Signals
Indicator
NA
PMVP
Relative Strength Index (RSI) 28.12 55.36
Support Level N/A $1.37
Resistance Level $3.42 $1.53
Average True Range (ATR) 0.18 0.08
MACD -0.04 0.01
Stochastic Oscillator 1.56 80.44

Price Performance

Historical Comparison
NA
PMVP

About NA Nano Labs Ltd

Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: